quinoxalines has been researched along with Eye Diseases in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bowman, RJ; Cope, J; Nischal, KK | 1 |
| Gordon, RN; Greenfield, DS; Lama, P; Liebmann, JM; Ritch, R | 1 |
| Lagrèze, WA | 1 |
1 trial(s) available for quinoxalines and Eye Diseases
| Article | Year |
|---|---|
Lack of cross-reactive allergic response to brimonidine in patients with known apraclonidine allergy.
Topics: Adrenergic alpha-Agonists; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Brimonidine Tartrate; Clonidine; Cross Reactions; Drug Hypersensitivity; Eye Diseases; Follow-Up Studies; Glaucoma; Humans; Middle Aged; Quinoxalines; Time Factors | 1998 |
2 other study(ies) available for quinoxalines and Eye Diseases
| Article | Year |
|---|---|
Ocular and systemic side effects of brimonidine 0.2% eye drops (Alphagan) in children.
Topics: Adolescent; Adrenergic alpha-Agonists; Antihypertensive Agents; Brimonidine Tartrate; Child; Child, Preschool; Eye Diseases; Female; Glaucoma; Humans; Infant; Infant, Newborn; Male; Ophthalmic Solutions; Quinoxalines; Sleep Stages; Syncope | 2004 |
[Neuroprotection. Bases and possibilities of a future clinical use].
Topics: Adrenergic alpha-Agonists; Animals; Apoptosis; Brimonidine Tartrate; Clinical Trials as Topic; Disease Models, Animal; Dopamine Agents; Eye Diseases; Forecasting; Glaucoma; Humans; Memantine; Neuroprotective Agents; Optic Neuritis; Quinoxalines; Retinal Diseases; Visual Fields | 2001 |